The health care sector is booming, due to the aging population in the United States. But there’s a subsector within health care that is doing particularly well: pet health care.petmeds-stock

Without a doubt, people love their pets. In fact, sometimes people will sacrifice their own well-being so that their furry friends are taken care of. This is a huge tailwind for PetMed Express Inc. (NASDAQ: PETS).

PetMed Express is a marketer of prescription and non-prescription pet medications, health products and supplies for dogs and cats. It is a licensed pharmacy which operates through the 1-800-PetMeds brand and dispenses prescription medications in all 50 states. It offers over 3,000 different products, including a variety of private label products. According to the company, it’s the largest pet pharmacy in the country.

PetMed Express is a very attractive dividend stock, because it offers a 4.3% dividend yield. This is more than double the average yield for the S&P 500 index. Even better, PetMed Express is a good opportunity for growth investors, too, with just a $333 million market capitalization. And there’s plenty of growth in store, because pet spending is booming.

The Bureau of Labor Statistics conducted a study on pet spending in the U.S. from 2007-2011 which found that there are about 218 million pets in the United States. According to the study, spending on pet care grew to $61 billion by 2011, and it’s very likely that pet spending has grown since then, along with the broader economic recovery.

Indeed, this growth is flowing right through to PetMed Express’ bottom line. The company recently reported a very strong quarter. It grew sales by 2.8% last quarter and net income grew 9.4% in the same period.

Growth was due primarily to an increase in average order value, which rose from $77 to $81 per order year-over-year. Management credited this rise to customers ordering higher-priced products, which is a good sign that the company enjoys pricing power.

PetMed Express operates a very lean business model, with low capital spending requirements outside of advertising. That is because the company is heavily geared toward online and mobile sales. In fact, online sales accounted for 80% of total sales last quarter.

As a result, PetMed Express generated $31 million in free cash flow last year. Its dividend cost just $13 million, which equates to a very comfortable 42% free cash flow payout ratio. This leaves plenty of room for dividend growth going forward.

All that cash is now piling up on the company’s balance sheet. At the end of last quarter, PetMed Express held more than $35 million in cash and cash equivalents. This amounts to more than 10% of the company’s market value. Moreover, it has no long-term debt on its balance sheet. Clearly, the company is in fantastic financial position and enjoys excellent liquidity.

PetMed Express offers a very high dividend yield, and actually grows its dividend regularly. It recently increased its dividend by 5%, which means the stock provides a high amount of current income, as well as the potential for future income through dividend growth.

There aren’t many industries that are booming in America right now, but pet spending is definitely one of them. Americans have shown an unshakeable commitment to their pets, and will do whatever is necessary to keep them happy and healthy.

In turn, PetMed Express is capitalizing on the boom in pet health care. The stock offers a very high yield, and the company does a great job of growing its dividend over time. This makes PetMed Express a hidden gem for steady dividend income.

Six times BIGGER Dividends – with this one stock 

The average yield of the Dow has sunk to 2.1%. That’s just sad. However, we know of one group of investors collecting up to $550 every 30 days from a little-known investment that yields a whopping 12%! That’s roughly six times bigger than the average yield of the Dow. If you’d like to tap into this income stream, and earn six times bigger dividends, click here for our full report on this opportunity. 

Published by Wyatt Investment Research at